## COVID-19 Vaccine Information

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Trail</th>
<th>Efficacy</th>
<th>Variants</th>
<th>Additional Dose Recommendations</th>
<th>Pediatrics</th>
<th>Specifics</th>
<th>Looking Ahead</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pfizer-BioNTech (mRNA)</strong></td>
<td>Phase 3 (12/20)</td>
<td>95%</td>
<td>Gamma, Delta</td>
<td>5 doses at 0, 3, 4, 12, 16 weeks</td>
<td>Ages 12+</td>
<td>Emergency Use Authorization (EUA)</td>
<td>[Updated: 11/01/2021]</td>
</tr>
<tr>
<td><strong>Moderna (mRNA)</strong></td>
<td>Phase 3 (12/20)</td>
<td>93.2%</td>
<td>Alpha, Beta, Gamma, Delta</td>
<td>2 doses at 0, 4 weeks</td>
<td>Ages 18+</td>
<td>EUA approved</td>
<td>[Updated: 11/01/2021]</td>
</tr>
<tr>
<td><strong>Janssen/J&amp;J</strong></td>
<td>Phase 2 (12/20)</td>
<td>66%</td>
<td>Alpha, Beta, Gamma, Delta</td>
<td>1 dose</td>
<td>Ages 18+</td>
<td>EUA approved</td>
<td>[Updated: 11/01/2021]</td>
</tr>
</tbody>
</table>

### Pfizer-BioNTech (mRNA)

- **Efficacy**: 95%
- **Variants**: Gamma, Delta
- **Additional Dose Recommendations**: 5 doses at 0, 3, 4, 12, 16 weeks
- **Pediatrics**: Ages 12+
- **Specifics**: Emergency Use Authorization (EUA)
- **Looking Ahead**: \[Updated: 11/01/2021\]

### Moderna (mRNA)

- **Efficacy**: 93.2%
- **Variants**: Alpha, Beta, Gamma, Delta
- **Additional Dose Recommendations**: 2 doses at 0, 4 weeks
- **Pediatrics**: Ages 18+
- **Specifics**: EUA approved
- **Looking Ahead**: \[Updated: 11/01/2021\]

### Janssen/J&J

- **Efficacy**: 66%
- **Variants**: Alpha, Beta, Gamma, Delta
- **Additional Dose Recommendations**: 1 dose
- **Pediatrics**: Ages 18+
- **Specifics**: EUA approved
- **Looking Ahead**: \[Updated: 11/01/2021\]

---

**Note:** The information provided is accurate as of the date indicated in the table. For the most current information, please visit the official websites of the respective vaccine manufacturers and regulatory bodies.